Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Products > Novel inhibitors

Novel inhibitors

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DC47438 Acid Ceramidase-IN-1
Acid Ceramidase-IN-1 is a potent and oral bioavailable acid ceramidase (AC, ASAH-1) inhibitor (hAC IC50=0.166 μM). Acid Ceramidase-IN-1 has excellent brain penetration in mice.
More description
DC47431 4-Maleimidosalicylic acid
4-Maleimidosalicylic acid is a polar maleimide, and does not suppress IL-2 production in JURKAT T cells.
More description
DC47423 ANAT inhibitor-2
ANAT inhibitor-2 is a ANAT inhibitor for canavan disease, with an IC50 value of 20 μM.
More description
DC47419 (Z)-PUGNAc
(Z)-PUGNAc is a potent O-GlcNAcase inhibitor. (Z)-PUGNAc is a vastly more potent inhibitor of O-GlcNAcase than the E form.
More description
DC47417 (±)13-HpODE
(±)13-HpODE (13-hydroperoxylinoleic acid) is a racemic mixture of hydroperoxides, which is produced by the oxidation of linoleic acid by lipoxygenase.
More description
DC47415 3-Phenylpropyl isothiocyanate
3-Phenylpropyl isothiocyanate has a stronger inhibitory effect on N-nitrosomethyl-benzylamine (NMBA) tumorigenesis. 3-Phenylpropyl isothiocyanate has chemopreventive effects.
More description
DC47414 1,4,7-Triazonane
1,4,7-Triazonane (1,4,7-Triazacyclononane), an intermediate in the synthesis of 1,4,7-trifunctionalized derivatives, is a possible reagent for compleximetric titrations with high cation-binding selectivity.
More description
DC47411 Anti-inflammatory agent 7
Anti-inflammatory agent 7 inhibits proinflammatory cytokines by blocking the NF-κB/MAPK signaling pathway in LPS-treated RAW 264.7 cells as well as mice.
More description
DC47408 28-O-β-D-Glucopyranosyl pomolic acid
28-O-β-D-Glucopyranosyl pomolic acid is a urokinase plasminogen activator inhibitor with IC50 at 37.82 μM.
More description
DC47406 Antileishmanial agent-2
Antileishmanial agent-2 shows submicromolar antileishmanial activity (IC50 = 0.29 μM) and a very high selectivity index with respect to mammalian cells.
More description
DC47401 Antileishmanial agent-1
Antileishmanial agent-1 exhibits the activity against L. amazonensis promastigotes (IC50 = 15.52 μM) and intracellular amastigotes (IC50 = 4.10 μM).
More description
DC47379 1,2-Didecanoylglycerol
1,2-Didecanoylglycerol, a synthetic diacylglycerol, is metabolized by platelets to 1,2-didecanoylphosphatidic acid (PA10) and activates protein kinase C (PKC).
More description
DC47378 (±)-1,2-Diolein
(±)-1,2-Diolein (1,2-Dioleoyl-rac-glycerol) is a PKC activator.
More description
DC47374 Aligeron
Aligeron is a non-selective prostaglandin (PG) antagonist, and has vasodilatory properties.
More description
DC47371 1-Bromo-6-chlorohexane
1-Bromo-6-chlorohexane is a PROTAC linker can be used in the synthesis of PROTACs.
More description
DC47335 ADTL-SA1215
ADTL-SA1215 is a first-in-class specific small-molecule activator of SIRT3 that modulates autophagy in triple negative breast cancer.
More description
DC47334 Ainsliadimer C
Ainsliadimer C, a potential activator of SIRT1, ameliorates inflammatory responses in adipose tissue.
More description
DC47332 Antiallergic agent-1
Antiallergic agent-1, a Src-family kinase inhibitor, may serve as a new valuable lead compound for future antiallergic drug discovery.
More description
DC47328 5,7-Dimethoxyflavanone
5,7-Dimethoxyflavanone shows potent antimutagenic activity against MeIQ mutagenesis in Ames test using the S. typhimurium TA100 and TA98 strains. And 5,7-Dimethoxyflavanone significantly and dose-dependently inhibits the inflammatory mediato
More description
DC47322 4-(Phenyldiazenyl)benzoic acid
4-(Phenyldiazenyl)benzoic acid is a photosensitive and photoswitchable TRPA1 agonist that can be used as pharmacological tools for study of pain signaling.
More description
DC58033 Nox inhibitor 1 Featured
Novel Nox inhibitor,N2-(3,4-Dimethylphenyl)-6-((4-(p-tolyl)piperazin-1- yl)methyl)-1,3,5-triazine-2,4-diamine
More description
DC58030 R-Avanafil Featured
Avanafil Impurity 8
More description
DC60171 ML353 (VU0478006) Featured
ML353 (VU0478006) is a ovel Silent Allosteric Modulator (SAM) of the Metabotropic Glutamate Receptor 5.
More description
DC58006 Z-ASTD-FMK Featured
Z-ASTD-FMK is a cell-permeant and irreversible inhibitor of endothelial monocyte-activated polypeptide II (EMAP II).
More description
DC58005 Z-FF-FMK Featured
Z-FF-FMK is a cell-permeant and irreversible inhibitor of cathepsin B and cathepsin L.
More description
DC60181 dCBP-1 Featured
dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP based on Cereblon ligand. dCBP-1 is exceptionally potent at killing multiple myeloma cells and can abolish the enhancer that drives MYC oncogene expression. As an efficient degrader of this unique class of acetyltransferases, dCBP-1 is a useful tool alongside domain inhibitors for dissecting the mechanism by which these factors coordinate enhancer activity in normal and diseased cells.
More description
DC46916 2-bromo-Hexadecanoic acid Featured
2-Bromohexadecanoic acid (2-BP, 2-bromopalmitate) is a nonmetabolisable analogue of palmitate and acts as a palmitoylation inhibitor. 2-Bromohexadecanoic acid can directly and irreversibly inhibit the palmitoyltransferase activity of all DHHC (Asp-His-His-Cys) proteins.
More description
DC36493 Dideoxyadenosine Featured
Dideoxyadenosine is konwn as 2′,3′-Dideoxyadenosine (ddA), a specific adenylyl cyclase inhibitor, is useful in biological process and pathway studies involving adenylyl cyclase activity and cAMP pool modulation.
More description
DC60144 MCULE-3408819416 Featured
MCULE-3408819416|DC Chemicals
More description
DC46834 Menin-MLL inhibitor 20,MRN73473 Featured
Menin-MLL inhibitor 20 is an irreversible menin-MLL interaction inhibitor with antitumor activities (WO2020142557A1, compound 6).
More description

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X